The decision to recall approximately three million sensors follows reports of potentially life-threatening errors in the ...

The Food and Drug Administration issued an alert about a “potentially high-risk issue” regarding malfunctioning Abbott ...

Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, Oct 16. We expect the company to post revenue of $10.6 billion and earnings of $1.20 on a per share and adjusted basis, aligning with ...

John Sims thought he knew everything about diabetes. As a child, he watched his father and uncles struggle to control the disease. Later, when he got married, he saw his father-in-law attempt to ...

Editor’s Note: This article originally appeared on Abbott’s website. ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today the launch of its Afinion™ 2 analyzer in ...

Anew alert from the U.S. Food and Drug Administration has warned that some Libre sensors from Abbott may give incorrect blood ...

ABBOTT PARK, Ill., Nov. 1, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced 'Countdown at a Crossroads,' which kicks off National Diabetes Awareness Month by taking over the Oculus Center ...

Though continuous glucose monitors have long been more widely used among people with Type 1 diabetes, new research has increasingly shown that the Type 2 population can majorly benefit from CGM ...

“The Second Circuit also found that the district court was within its discretion to enter judgment without considering lesser sanctions due to Goldman’s repeated discovery abuses and ...